# Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance), Division 2: ABBREVIATION LIST

Extent: E+W+S+N.I.

1. AFP acute flaccid paralysis
2. AIDS acquired immune deficiency syndrome
3. AMR antimicrobial resistance
4. Anti-HBc hepatitis B core antibody
5. anti-HCV hepatitis C virus specific antibody
6. ARI acute respiratory infection
7. BAL broncho-alveolar lavage
8. BCG Bacille de Calmette et Guérin
9. BJ bone and joint infection
10. BJ-BONE osteomyelitis
11. BJ-DISC disc space infection
12. BJ-JNT joint or bursa infection
13. BoNT botulinum neurotoxin
14. BSI bloodstream infection
15. C-CVC catheter-related — central venous catheter
16. CDAD Clostridium difficile associated diarrhoea
17. CFU colony-forming unit
18. CJD Creutzfeldt-Jakob disease
19. CMV cytomegalovirus
20. CNRL EU Community Network of Reference Laboratories for human influenza
21. CNS central nervous system
22. CNS-IC central nervous system infection — intracranial infection
23. CNS-MEN central nervous system infection — meningitis or ventriculitis
24. CNS-SA central nervous system infection — spinal abscess without meningitis
25. C-PVC catheter-related — peripheral venous catheter
26. CRI catheter-related infection
27. CRS Congenital rubella syndrome
28. CRT capillary refilling time
29. CSF Cerebrospinal fluid
30. CT scan computed tomography scan
31. CVS cardiovascular system infection
32. CVS-CARD cardiovascular system infection — myocarditis or pericarditis
33. CVS-ENDO cardiovascular system infection — endocarditis
34. CVS-MED cardiovascular system infection — mediastinitis
35. CVS-VASC cardiovascular system infection — arterial or venous infection
36. DFA direct fluorescent antibody
37. DFA-TP direct fluorescent antibody test for Treponema pallidum
38. DNA deoxyribonucleic acid
39. DPA distal protected aspirate
40. EARS-Net European Antimicrobial Resistance Surveillance Network
41. ECDC European Centre for Disease Prevention and Control
42. ECOFFs epidemiological cut-off values
43. EEG electroencephalography
44. EENT eye, ear, nose, throat, or mouth infection
45. EENT-CONJ eye, ear, nose, throat, or mouth infection — conjunctivitis
46. EENT-EAR eye, ear, nose, throat, or mouth infection — ear mastoid
47. EENT-EYE eye, ear, nose, throat, or mouth infection — eye, other than conjunctivitis
48. EENT-ORAL eye, ear, nose, throat, or mouth infection — oral cavity (mouth, tongue, or gums)
49. EENT-SINU eye, ear, nose, throat, or mouth infection — sinusitis
50. EENT-UR eye, ear, nose, throat, or mouth infection — upper respiratory tract, pharyngitis, laryngitis, epiglottitis
51. EFNS European Federation of Neurological Societies
52. EIA enzyme immunoassay
53. ELISA enzyme-linked immunosorbent assay
54. EM electron microscopy
55. EUCAST European Committee on Antimicrobial Susceptibility Testing
56. FAMA fluorescent antibody to membrane antigen
57. FTA-abs fluorescent treponemal antibody absorption
58. FUO fever of unknown origin
59. GI gastrointestinal system infection
60. GI-CDI gastrointestinal system infection — Clostridium difficile infection
61. GI-GE gastrointestinal system infection — gastroenteritis (excl. CDI)
62. GI-GIT gastrointestinal system infection — gastrointestinal tract (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis
63. GI-HEP gastrointestinal system infection — hepatitis
64. GI-IAB gastrointestinal system infection — intraabdominal, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere
65. HAI healthcare-associated infections
66. HbeAg hepatitis B e antigen
67. HbsAg hepatitis B surface antigen
68. HBV-DNA hepatitis B nucleic acid
69. HCV-core hepatitis C virus core antigen
70. HCV-RNA hepatitis C virus nucleic acid
71. HIV human immunodeficiency virus
72. HUS haemolytic-uraemic syndrome
73. IAP intubation-associated pneumonia
74. IFA indirect fluorescent antibody
75. IgG immunoglobulin G
76. IgM immunoglobulin M
77. ILI influenza-like illness
78. LGV lymphogranuloma (venereum)
79. LPS lipopolysaccharides
80. LRI lower respiratory tract infection, other than pneumonia
81. LRI-BRON lower respiratory tract infection — bronchitis, tracheobronchitis, bronchiolitis, tracheitis, without evidence of pneumonia
82. TBE Tick-borne encephalitis

---
Source: https://www.legislation.gov.uk/eudn/2018/945/annex/II/division/2 (the official version)
Page: https://openlegislation.uk/eu-decision-2018-945/annex-II/division-2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.